Goldman Sachs’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
Other funds holding ZNTL
SFCM
Goldman Sachs's ZNTL Position: Q3 2026 in Review
Goldman Sachs reduced its Zentalis Pharmaceuticals (ZNTL) stake by 51% in Q3 2026, selling an estimated $765K and leaving 182,865 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #5703.
Goldman Sachs first reported a position in ZNTL in Q2 2020 and has held it in 26 quarters since. The position peaked at $20.7M in Q2 2023. 127 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.
- Goldman Sachs held 182,865 shares of Zentalis Pharmaceuticals worth $507K as of Q3 2026.
- Goldman Sachs sold 189,699 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $765K.
- Zentalis Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5703 holding.
- Goldman Sachs first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 26 quarters since.
- Goldman Sachs's Zentalis Pharmaceuticals position peaked at $20.7M in Q2 2023.
- 127 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.